Analysts Predict Upward Trajectory for Novo Nordisk and Eli Lilly Despite Recent Surge in Shares
Friday, 12 April 2024, 13:11
Analysts Bullish on Novo Nordisk and Eli Lilly
Novo Nordisk and Eli Lilly, the leading players in the obesity-drug sector, are poised for continued success according to analysts.
Room for Growth
Novo Nordisk and Eli Lilly, the dynamic duo of the weight-loss drug world, still have plenty of upside even after their shares have surged over the past 12 months.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.